Improvement in Patient-Reported Emotional Symptoms and Activity Limitations Due to Hair Loss in Patients With Alopecia Areata Treated With Ritlecitinib: Additional Analyses From ALLEGRO-2b/3

October 2025 in “ International Journal of Dermatology ”

Ernest H. Law, Bintu Sherif, Arash Mostaghimi, Brett King, Rodney Sinclair, Natasha Atanaskova Mesinkovska, Kent A. Hanson, Dane Korver, Costel Chirila

alopecia areata ritlecitinib

TLDR Ritlecitinib improves emotional well-being and activity levels in alopecia areata patients.

This study, part of the ALLEGRO-2b/3 trial, evaluated the impact of ritlecitinib on emotional symptoms and activity limitations in 325 patients with alopecia areata. By Week 48, those on a 50-mg dose of ritlecitinib showed significantly greater improvements in emotional symptoms, such as self-consciousness and embarrassment, and in activity limitations, particularly in outdoor activities and exercise, compared to those on a 10-mg dose. The findings suggest that ritlecitinib can alleviate the psychosocial burden associated with hair loss in alopecia areata patients, enhancing their quality of life, although longer follow-up may be needed to observe full benefits.

View this study on onlinelibrary.wiley.com →

Discuss this study in the Community →

Research cited in this study

16 / 16 results

research European Expert Consensus Statement on the Systemic Treatment of Alopecia Areata

4 citations , January 2024 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology”

Baricitinib and ritlecitinib are recommended for severe alopecia areata, with other treatments available off-label.

research Ritlecitinib: First Approval

84 citations , August 2023 in “Drugs”

Ritlecitinib is approved in the USA and Japan for treating severe hair loss in people aged 12 and older.

research A Plain Language Summary on Ritlecitinib Treatment for Adults and Adolescents with Alopecia Areata

7 citations , July 2023 in “Immunotherapy”

Ritlecitinib works well and is safe for treating alopecia areata.

research The Invisible Impact Of A Visible Disease: Psychosocial Impact Of Alopecia Areata

40 citations , June 2023 in “Dermatology and Therapy”

Alopecia Areata causes emotional stress and stigma, but those with severe hair loss may adapt better.

research Efficacy and Safety of Ritlecitinib in Adults and Adolescents With Alopecia Areata: A Randomised, Double-Blind, Multicentre, Phase 2b–3 Trial

227 citations , April 2023 in “The Lancet”

Ritlecitinib effectively treats alopecia areata and is well-tolerated.

research Alopecia Areata: Burden of Disease, Approach to Treatment, and Current Unmet Needs

1 citations , March 2023 in “Clinical, Cosmetic and Investigational Dermatology”

Current treatments for Alopecia Areata have mixed success, and there's a need for better, more accessible options and support for affected individuals.

research The Burden of Alopecia Areata: A Scoping Review Focusing on Quality of Life, Mental Health, and Work Productivity

10 citations , January 2023 in “Journal of the European Academy of Dermatology and Venereology”

Alopecia areata greatly affects people's life quality, mental health, and work life.

research The Association of Alopecia Areata-Related Emotional Symptoms with Work Productivity and Daily Activity Among Patients with Alopecia Areata

29 citations , December 2022 in “Dermatology and Therapy”

Emotional symptoms from alopecia areata reduce work productivity and daily activity.

research Integrated Safety Analysis of Baricitinib in Adults With Severe Alopecia Areata From Two Randomized Clinical Trials

25 citations , November 2022 in “British journal of dermatology/British journal of dermatology, Supplement”

Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.

research Two Phase 3 Trials of Baricitinib for Alopecia Areata

148 citations , March 2022 in “The New England Journal of Medicine”

Baricitinib was effective in treating alopecia areata in two major trials.

research Validation of the Alopecia Areata Patient Priority Outcomes Questionnaire in Adults and Adolescents with Alopecia Areata

22 citations , November 2021 in “Dermatology and Therapy”

The AAPPO questionnaire is a reliable tool for assessing hair loss impact in alopecia areata patients.

research Patient Perspectives of the Social, Emotional and Functional Impact of Alopecia Areata: A Systematic Literature Review

67 citations , March 2021 in “Dermatology and Therapy”

Alopecia areata greatly harms quality of life, causing emotional and social issues.